{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T18:04:28Z","timestamp":1769882668559,"version":"3.49.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"AbbVie Pty Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40121-024-00926-1","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T13:02:53Z","timestamp":1709298173000},"page":"549-564","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Direct-Acting Antivirals Remain Cost-Effective Treatments for Chronic Hepatitis C in Australia Despite Changes to the Treated Population and the Availability of Retreatment: The Glecaprevir\/Pibrentasvir (Maviret\u00ae) Example"],"prefix":"10.1007","volume":"13","author":[{"given":"Emma","family":"Warren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda J. C.","family":"Castles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian C.","family":"Sharratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aitor","family":"Arteaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"key":"926_CR1","unstructured":"Commonwealth Government of Australia. 5th National Hepatitis C Strategy https:\/\/www.health.gov.au\/sites\/default\/files\/documents\/2022\/06\/fifth-national-hepatitis-c-strategy-2018-2022.pdf. Accessed Mar 2023."},{"key":"926_CR2","unstructured":"Burnet Institute and Kirby Institute. Australia\u2019s progress towards hepatitis C elimination: annual report 2020. Melbourne: Burnet Institute; 2020. https:\/\/burnet.edu.au\/system\/asset\/file\/4532\/2020-progress-towards-hepatitis-c-elim-report.pdf. Accessed March 2023."},{"key":"926_CR3","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jval.2014.07.011","volume":"17","author":"E Warren","year":"2014","unstructured":"Warren E, Wright A, Jones B. Cost-effectiveness of telaprevir in patients with genotype 1 hepatitis C in Australia. Value in Health. 2014;17:792\u2013800.","journal-title":"Value in Health"},{"issue":"1","key":"926_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/13696998.2016.1227827","volume":"20","author":"H McElroy","year":"2017","unstructured":"McElroy H, Roberts S, Thompson A, Angus P, McKenna S, Warren E, Musgrave S. Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study. J Med Econ. 2017;20(1):72\u201381.","journal-title":"J Med Econ"},{"issue":"7","key":"926_CR5","doi-asserted-by":"publisher","first-page":"892","DOI":"10.7150\/ijms.43079","volume":"17","author":"H Zeng","year":"2020","unstructured":"Zeng H, Li L, Hou Z, et al. Direct-acting antiviral in the treatment of chronic hepatitis C: bonuses and challenges. Int J Med Sci. 2020;17(7):892\u2013902.","journal-title":"Int J Med Sci"},{"key":"926_CR6","unstructured":"PBAC Outcomes. https:\/\/www.pbs.gov.au\/pbs\/industry\/listing\/elements\/pbac-meetings\/pbac-outcomes. Accessed Mar 2023."},{"key":"926_CR7","unstructured":"Schedule of Pharmaceutical benefits (Summary of Changes) Archive. https:\/\/www.pbs.gov.au\/info\/publication\/schedule\/archive. Accessed Mar 2023."},{"key":"926_CR8","unstructured":"Burnet Institute and Kirby Institute. Australia\u2019s progress towards hepatitis C elimination: annual report 2021. Melbourne: Burnet Institute; 2021. https:\/\/burnet.edu.au\/system\/asset\/file\/5001\/BurnetKirby-hepC-2021-report.pdf. Accessed Mar 2023."},{"key":"926_CR9","unstructured":"The Kirby Institute. Monitoring hepatitis C treatment uptake in Australia (Issue 12). The Kirby Institute, UNSW Sydney, NSW, Australia, July 2022. https:\/\/kirby.unsw.edu.au\/report\/monitoring-hepatitis-c-treatment-uptake-australia-issue-12-july-2022. Accessed Mar 2023."},{"issue":"1","key":"926_CR10","doi-asserted-by":"publisher","first-page":"S289","DOI":"10.1016\/S0168-8278(18)30798-0","volume":"68","author":"S Christensen","year":"2018","unstructured":"Christensen S, Ingiliz P, Schulze zur Wiesch J, et al. Significant changes of HCV patient characteristics over time in the era of direct antiviral agent therapy\u2014are all HCV subpopulations treated similarly?\u2014Results from the German hepatitis C cohort. J Hepatol. 2018;68(1):S289\u201390.","journal-title":"J Hepatol"},{"issue":"7","key":"926_CR11","first-page":"319","volume":"25","author":"N Tsai","year":"2019","unstructured":"Tsai N, Bacon B, Curry M, et al. Changing demographics among populations prescribed HCV treatment, 2013\u20132017. Am J Manag Care. 2019;25(7):319\u201323.","journal-title":"Am J Manag Care"},{"issue":"13","key":"926_CR12","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.3748\/wjg.v29.i13.2015","volume":"29","author":"M Brzd\u0119k","year":"2023","unstructured":"Brzd\u0119k M, Zar\u0119bska-Michaluk D, Rzymski P, et al. Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era. World J Gastroenterol. 2023;29(13):2015\u201333.","journal-title":"World J Gastroenterol"},{"key":"926_CR13","unstructured":"Burnet Institute and Kirby Institute. Australia\u2019s progress towards hepatitis\u00a0C elimination: annual report 2022. Melbourne: Burnet Institute; 2022. https:\/\/burnet.edu.au\/system\/asset\/file\/5604\/Australia_s_progress_towards_hepatitis_C_elimination_annual_report_2022.pdf. Accessed Mar 2023."},{"key":"926_CR14","unstructured":"Public Summary Document for glecaprevir\/pibrentasvir (Maviret\u00ae). November 2017. https:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2017-11\/files\/glecaprevir-with-pibrentasvir-psd-november-2017.pdf. Accessed Mar 2023."},{"key":"926_CR15","unstructured":"Public Summary Document for paritaprevir\/ritonavir\/ombitasvir (Viekira PAK\u00ae). July 2015. https:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2015-07\/files\/paritaprevir-ritonavir-ombitasvir-dasabuvir-psd-july-2015.pdf. Accessed Mar 2023."},{"key":"926_CR16","first-page":"244A","volume":"34","author":"J McHutchison","year":"2001","unstructured":"McHutchison J, Davis G, Esteban J, et al. Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon alpha-2B alone or in combination with ribavirin. Hepatology. 2001;34:244A.","journal-title":"Hepatology"},{"issue":"6","key":"926_CR17","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/cid\/civ948","volume":"62","author":"B Simmons","year":"2016","unstructured":"Simmons B, Saleem J, Hill A, et al. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis. 2016;62(6):683\u201394.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"926_CR18","doi-asserted-by":"publisher","first-page":"e2164","DOI":"10.1093\/cid\/ciaa1500","volume":"73","author":"JS Doyle","year":"2021","unstructured":"Doyle JS, van Santen DK, Iser D, et al. Micro-elimination of hepatitis C among people with HIV coinfection: declining incidence and prevalence accompanying a multi-center treatment scale-up trial. Clin Infect Dis. 2021;73(7):e2164\u201372.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"926_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/jvh.13705","volume":"29","author":"J Carson","year":"2020","unstructured":"Carson J, Hajarizadeh B, Hanson J, et al. Retreatment for hepatitis C virus direct-acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohort. J Viral Hepatitis. 2020;29(8):661\u201376.","journal-title":"J Viral Hepatitis"},{"key":"926_CR20","unstructured":"Gastroenterological Society of Australia. Hepatitis C Virus Infection Consensus Statement Working Group. Australian recommendations for the management of hepatitis C virus infection: a consensus statement (2022). Melbourne, 2022. http:\/\/www.hepcguidelines.org.au\/wp-content\/uploads\/2023\/02\/hepatitis-C-virus-infection-a-consensus-statement-2022-100223.pdf. Accessed Mar 2023."},{"key":"926_CR21","unstructured":"Australasian Society for HIV Medicine (ASHM). General practitioners and hepatitis C. Darlinghurst, NSW. 2012. https:\/\/www.aph.gov.au\/DocumentStore.ashx?id=18b58c4b-7aa3-4ad3-98f3-66cb50fbcdb7&subId=303939. Accessed Mar 2023."},{"key":"926_CR22","unstructured":"Public Summary Document for glecaprevir\/pibrentasvir (Maviret\u00ae). July 2017. https:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2017-07\/files\/glecaprevir-with-pibrentasvir-psd-july-2017.pdf. Accessed Mar 2023."},{"key":"926_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","volume":"69","author":"M Puoti","year":"2018","unstructured":"Puoti M, Foster GR, Wang S, et al. High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: an integrated analysis of HCV genotype 1\u20136 patients without cirrhosis. J Hepatol. 2018;69:293\u2013300.","journal-title":"J Hepatol"},{"key":"926_CR24","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1016\/j.cgh.2020.06.044","volume":"18","author":"E Zuckerman","year":"2020","unstructured":"Zuckerman E, Gutierrez J, Dylla D, et al. Eight weeks of treatment with glecaprevir\/pibrentasvir is safe and efficacious in an integrated analysis of treatment na\u00efve patients with hepatitis C virus infection. Clin Gastroenterol Hepatol. 2020;18:2544\u201353.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"926_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103422","volume":"96","author":"M Carson","year":"2021","unstructured":"Carson M, Hajarizadeh B, Hanson J, et al. Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort. Int J Drug Policy. 2021;96: 103422.","journal-title":"Int J Drug Policy"},{"key":"926_CR26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ijid.2020.04.022","volume":"96","author":"M El Kassas","year":"2020","unstructured":"El Kassas M, Alboraie M, El Badry M, et al. Retreatment of chronic hepatitis C patients who failed previous therapy with directly acting antivirals: a multicenter study. Int J Infect Dis. 2020;96:367\u201370.","journal-title":"Int J Infect Dis"},{"key":"926_CR27","unstructured":"Australian Bureau of Statistics life tables. https:\/\/www.abs.gov.au\/statistics\/people\/population\/life-tables\/latest-release#data-downloads. Accessed Mar 2023."},{"key":"926_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/hep.27151","volume":"60","author":"L Hagan","year":"2014","unstructured":"Hagan L, Sulkowski M, Schinazi R. Cost analysis of sofosbuvir\/ribavirin versus sofosbuvir\/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible\/intolerant individuals. Hepatology. 2014;60:37\u201345.","journal-title":"Hepatology"},{"key":"926_CR29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/jvh.12111","volume":"20","author":"LM Hagan","year":"2013","unstructured":"Hagan LM, Yang Z, Ehteshami M, Schinazi RF. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepatol. 2013;20:847\u201357.","journal-title":"J Viral Hepatol"},{"key":"926_CR30","unstructured":"Schedule of Pharmaceutical Benefits. https:\/\/www.pbs.gov.au\/pbs\/industry\/listing\/elements\/deeds-agreement\/b-background. Accessed Mar 2023."},{"key":"926_CR31","unstructured":"Australian Government Therapeutic Good Administration. Glecaprevir\/pibrentasvir (Maviret\u00ae) product information. https:\/\/www.tga.gov.au\/sites\/default\/files\/2023-03\/auspar-maviret-230220-pi.pdf. Accessed Mar 2023."},{"key":"926_CR32","unstructured":"Australian Government Therapeutic Good Administration. sofosbuvir\/velpatasvir (Epclusa\u00ae) product information. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2016-PI-02886-1&d=20230711172310101. Accessed Mar 2023."},{"key":"926_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.5694\/mja12.10014","volume":"196","author":"H Gidding","year":"2012","unstructured":"Gidding H, Law M, Amin J, et al. Hepatitis C treatment outcomes in Australian clinics. Med J Aust. 2012;196:633\u20137.","journal-title":"Med J Aust"},{"key":"926_CR34","doi-asserted-by":"crossref","unstructured":"Szabo SM, Lane S, Samp J, Polo B, Levy AR. Preference values for hepatitis C-related health states from members of the general public in Australia, Brazil, France, Italy and Spain. In: Presented at the international society for pharmacoeconomics and outcomes research (ISPOR) 20th annual international meeting, May 2015, Philadelphia, USA. https:\/\/www.ispor.org\/heor-resources\/presentations-database\/presentation\/ispor-20th-annual-international-meeting\/preference-values-for-hepatitis-c-related-health-states-from-members-of-the-general-public-in-australia-brazil-france-italy-and-spain. Accessed Mar 2023.","DOI":"10.1016\/j.jval.2015.03.1409"},{"key":"926_CR35","unstructured":"Public Summary Document for ledipasvir\/sofosbuvir (Harvoni\u00ae). March 2015 https:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2015-03\/Files\/ledipasvir-sofosbuvir-psd-march-2015.pdf. Accessed Mar 2023."},{"key":"926_CR36","unstructured":"Data on file. Weighted average of utility scores taken from glecaprevir\/pibrentasvir trials. In the weighting, PBS script data were used to determine the proportional use of 8, 12 and 16 weeks treatment with glecaprevir\/pibrentasvir."},{"issue":"1","key":"926_CR37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1017\/S0266462312000724","volume":"29","author":"J Mauskopf","year":"2013","unstructured":"Mauskopf J, Chirila C, Masaquel C, et al. Relationship between financial impact and coverage of drugs in Australia. Int J Technol Assess Health Care. 2013;29(1):92\u2013100.","journal-title":"Int J Technol Assess Health Care"},{"key":"926_CR38","unstructured":"Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2021. Sydney: Kirby Institute, UNSW Sydney; 2021. https:\/\/kirby.unsw.edu.au\/sites\/default\/files\/kirby\/report\/Annual-Surveillance-Report-2021_HCV_221107.pdf. Accessed Mar 2023."},{"key":"926_CR39","unstructured":"Australian Government, Department of Health. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee, version 5.0, 2016. https:\/\/pbac.pbs.gov.au\/information\/printable-version-of-guidelines.html. Accessed Mar 2023."},{"issue":"4","key":"926_CR40","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s10620-020-06281-8","volume":"66","author":"MF Yuen","year":"2021","unstructured":"Yuen MF, Liu SH, Seto WK, et al. Cost-utility of all-oral direct-acting antiviral regimens for the treatment of genotype 1 chronic hepatitis c virus-infected patients in Hong Kong. Dig Dis Sci. 2021;66(4):1315\u201326.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"926_CR41","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s11096-018-0628-6","volume":"40","author":"SC Nasser","year":"2018","unstructured":"Nasser SC, Mansour H, Abi Nader T, Metni M. Cost-effectiveness of novel treatment of hepatitis C virus in Lebanese patients. Int J Clin Pharm. 2018;40(3):693\u20139.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"926_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169401","volume":"12","author":"JT Stahmeyer","year":"2017","unstructured":"Stahmeyer JT, Rossol S, Liersch S, et al. Cost-effectiveness of treating hepatitis C with sofosbuvir\/ledipasvir in Germany. PLoS ONE. 2017;12(1): e0169401.","journal-title":"PLoS ONE"},{"issue":"10","key":"926_CR43","first-page":"621","volume":"110","author":"J Mar","year":"2018","unstructured":"Mar J, Ibarrondo O, Mart\u00ednez-Baz I, et al. Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals. Span J Gastroenterol. 2018;110(10):621\u20138.","journal-title":"Span J Gastroenterol"},{"issue":"6","key":"926_CR44","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/hep.27736","volume":"61","author":"AJ Leidner","year":"2015","unstructured":"Leidner AJ, Chesson HW, Xu F, et al. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology. 2015;61(6):1860\u20139.","journal-title":"Hepatology"},{"issue":"6","key":"926_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217964","volume":"14","author":"A Chaillon","year":"2019","unstructured":"Chaillon A, Mehta SR, Hoenigl M, et al. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PLoS ONE. 2019;14(6): e0217964.","journal-title":"PLoS ONE"},{"key":"926_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2021.100316","volume":"18","author":"DN Scott","year":"2021","unstructured":"Scott DN, Palmer MA, Tidhar MT, et al. Assessment of the cost-effectiveness of Australia\u2019s risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study. Lancet Region Health West Pacific. 2021;18: 100316.","journal-title":"Lancet Region Health West Pacific"},{"key":"926_CR47","first-page":"1","volume":"36","author":"S Shih","year":"2023","unstructured":"Shih S, Cheng Q, Carson J, et al. Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis. Lancet. 2023;36:1\u201314.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"926_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jgh.12677","volume":"29","author":"W Sievert","year":"2014","unstructured":"Sievert W, Razavi H, Estes C, et al. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. J Gastroenterol Hepatol. 2014;29(Suppl 1):1\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"926_CR49","unstructured":"Australian Commonwealth Department of Human Services Pharmaceutical Benefits Scheme (PBS) 10% sample data. (The 10% sample is made available by the Australian government to approved data custodians for the purposes of research)"},{"key":"926_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15170","volume":"15","author":"D Hartwell","year":"2011","unstructured":"Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV\/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess. 2011;15:1\u201312.","journal-title":"Health Technol Assess"},{"issue":"8","key":"926_CR51","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1177\/135965350601100811","volume":"11","author":"M Yu","year":"2006","unstructured":"Yu M, Lin S, Chunag W, et al. A sustained virological response to interferon or interferon\/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther. 2006;11(8):985\u201394.","journal-title":"Antivir Ther"},{"key":"926_CR52","volume-title":"Epidemiological and economic impact of potential increased hepatitis C treatment uptake in Australia 2010","author":"The Kirby Institute (previously National Centre in HIV Epidemiology and Clinical Research)","year":"2010","unstructured":"The Kirby Institute (previously National Centre in HIV Epidemiology and Clinical Research). Epidemiological and economic impact of potential increased hepatitis C treatment uptake in Australia 2010. Sydney: The University of New South Wales; 2010."},{"issue":"3","key":"926_CR53","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1365-2036.2010.04370.x","volume":"32","author":"W Alazawi","year":"2010","unstructured":"Alazawi W, Cunningham J, Dearden JG. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010;32(3):344\u201355.","journal-title":"Aliment Pharmacol Ther"},{"key":"926_CR54","unstructured":"The Kirby Institute (previously National Centre in HIV Epidemiology and Clinical Research). HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2013"},{"key":"926_CR55","unstructured":"Cancer Institute NSW. Cancer survival in NSW 2002\u20132006. June 2012. https:\/\/www.cancer.nsw.gov.au\/getattachment\/1168be14-b79a-408d-9d41-35b99fd4959f\/cancer-survival-in-nsw-2002-06.pdf. Accessed Mar 2023."},{"key":"926_CR56","unstructured":"Thursfield V, Farrugia H, Karahalios E, Giles G. Cancer Survival in Victoria 2012: estimates of survival for 2006\u20132010 (and comparisons with earlier periods). Cancer Council Victoria, Melbourne 2012. http:\/\/www.cancervic.org.au\/research\/registry-statistics\/cancer-in-victoria. Accessed Mar 2023."},{"key":"926_CR57","unstructured":"Australian and New Zealand Liver Transplant Registry. ANZLTR 25th annual report 2014. https:\/\/www.anzlitr.org\/annual-reports\/. Accessed Mar 2023."},{"key":"926_CR58","unstructured":"Australian Government Medicare Benefits Schedule. http:\/\/www.mbsonline.gov.au\/internet\/mbsonline\/publishing.nsf\/Content\/Home. Accessed Mar 2023."},{"key":"926_CR59","unstructured":"Australian Bureau of Statistics. Consumer price index (medical and hospital services) https:\/\/www.abs.gov.au\/statistics\/economy\/price-indexes-and-inflation\/consumer-price-index-australia\/latest-release#data-downloads. Accessed Mar 2023."},{"key":"926_CR60","unstructured":"Australian Government, Department of Health. AR-DRG cost weights for inpatient episodes, Round 24, version 10.0 (2019\u201320). https:\/\/www.ihacpa.gov.au\/resources\/national-hospital-cost-data-collection-nhcdc-public-hospitals-report-round-24-financial-year-2019-20. Accessed Mar 2023."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00926-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-00926-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00926-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T06:07:12Z","timestamp":1711519632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-00926-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["926"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-00926-1","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"7 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No honoraria or payments were made for authorship. Financial arrangements of the authors with companies whose products may be related to the present report are listed as declared by the authors: Belinda Castles, Gillian Sharratt, and Aitor Arteaga are full-time employees of AbbVie. Emma Warren has served as a consultant for AbbVie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}